Risk Assessment in Patients With Tricuspid Valve Regurgitation: MELD and Beyond
- PMID: 33181244
- DOI: 10.1016/j.jacc.2020.11.009
Risk Assessment in Patients With Tricuspid Valve Regurgitation: MELD and Beyond
Keywords: MELD; risk assessment; tricuspid regurgitation.
Conflict of interest statement
Author Disclosures Dr. Adams’ institution the Icahn School of Medicine at Mount Sinai receives royalties from Edwards Lifesciences and Medtronic for mitral and tricuspid repair rings invented by Dr. Adams; and he has served as national co-principal investigator of the Medtronic APOLLO and Abbott TRILUMINATE FDA Pivotal Trials. Dr. Zaidi has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Prognostic Role of Hepatorenal Function Indexes in Patients With Ebstein Anomaly.J Am Coll Cardiol. 2020 Dec 22;76(25):2968-2976. doi: 10.1016/j.jacc.2020.10.035. J Am Coll Cardiol. 2020. PMID: 33334426 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
